- Dombek BD (1983) Metal hydrides in homogeneous catalytic reduction of carbon monoxide. Ann NY Acad Sci 415:176 -190.
- Mandal SK, Ho DM, Orchin M (1993) Reactions of electrophiles with manganese(I) and rhenium(I) alkoxide complexes: reversible absorption of atmospheric CO2. Organometallics 12:1714 -1719.
- Mandal SK, Ho DM, Orchin M (1991) A convenient synthesis of the manganese and rhenium alkoxides and phenoxides fac-(CO)3(dppe)MOR (R = CH3, C2H5, C6H5; dppe = l,2-Bis(diphenylphosphino)ethane). X-ray structure of fac- (CO)3(dppe)ReOC6H5. Inorg Chem 30:2244 -2248.
- O’keiffe LS, Mitchell AC, Becker TM, Ho DM, Mandal SK (2000) Reactions of [(CO)3(P-P)Mn]2 with primary alcohols, where, P-P is dppe {Ph2P(CH2)2PPh2}, dppp {Ph2P(CH2)3PPh2}, dppb {Ph2P(CH2)4PPh2}, dpppe {Ph2P(CH2)5PPh2}, dtpe {(p- tol)2P(CH2)2P(p-tol)2}, or dcpe {(chex)2P(CH2)2P(chex)2}. Synthesis of fac-(CO)3(P- P)MnH and the X-ray structure of fac-(CO)3(dtpe)MnH. J Organomet Chem 613:13-18.
- Mandal SK, Feldman J, Orchin M (1994) A New route to manganese and rhenium carbonyl tetrafluoroborate salts and an improved procedure for preparing their precursor hydrides. J Coord Chem 33:219 -221.
- Orchin M, Mandal SK, Feldman J, Lee W-Z, Darensbourg DJ (1998) Tricarbonyl(hydrido)[1,2-bis(diphenylphosphino)ethane]manganese as precursor to labile site derivatives. Inorg Synth 32:298 -302.
- Kimari DM, Duzs-Moore AM, Cook J, Miller KE, Budzichowski TA, Ho DM, Mandal SK (2005) One-pot synthesis and the X-ray structures of rhenium(I) diphosphine hydrides, fac-(CO)3(P–P)ReH [P–P = dppp, dppb, and dppfe]. Inorg Chem Commun 8:14 -17.
- Johnson K, Frazier T, Becker TM, Miller K, Ho DM, Krause-Bauer J, Mandal SK (2001) One-pot synthesis of manganese(I) and rhenium(I) alkylcarbonato complexes, fac-(CO)3(dppp)MOC(O)OR. Possible trapping of intermediate diphosphine dimers, [(CO)3(dppp)M]2. Inorg Chem Commun 4:602 -05.
- Orsa DK, Haynes GK, Pramanik SK, Iwunze MO, Greco GE, Krause JA, Ho DM, Williams AL, Hill DA, Mandal SK (2007) Synthesis, characterization, and fluorescence and cytotoxicity studies of a tetrarhenium molecular rectangle. Inorg Chem Commun 10:821 -824.
- Vieyra FEM, Cattaneo M, Fagalde F, Bozoglián F, Llobet A, Katz NE (2011) Influence of the linker length on the host–guest properties of alkoxy- and polypyridine-bridged molecular rectangles of formulae {[Re(CO)3(OC5H11)]4(L)2}, with L = 4-pyridinealdazine and 4,4′-azobis(pyridine). Inorg Chim Acta 374:247-252.
- See Supplementary Information for its structure.
- Orsa DK, Nettles CR, Pramanik SK, Iwunze MO, Greco GE, Krause JA, Mandal SK (2009) Cytotoxic effects of rhenium (I) carbonyl complexes on prostate cancer cell lines, in: A.T. Meridith (Ed.), Handbook of Prostate Cancer Cell Research: Growth, Signalling, Survival, Nova Science Publishers, Inc., New York, 323-362.
- Oliveira CG, Romero-Canelón I, Coverdale JPC, Maia PIS, Clarkson GJ, Deflon V M, Sadler PJ (2020) Novel tetranuclear PdII and PtII anticancer complexes derived from pyrene thiosemicarbazones. Dalton Trans 49:9595 -9604.
- Sun B, Sundaraneedi MK, Southam HM, Poole RK, Musgrave IF, Keene FR, Collins JG (2019) Synthesis and biological properties of tetranuclear ruthenium complexes containing the bis[4(4′-methyl-2,2′-bipyridyl)]-1,7-heptane ligand, Dalton Trans. 48:14505 -14515.
- Aouaidjia F, Messai A, Siab R, Ayesh AI (2017) A new tetranuclear copper(II)complex using a Schiff base ligand: synthesis, structural, and magnetic studies. Polyhedron 133:257- 263.
- Lin Y-Y, Lai S-W, Che C-M, Cheung K-K, Zhou ZY (2002) Luminescent tetranuclear silver(I) arylacetylide complexes bearing tricyclohexylphosphine ligands: synthesis, molecular structures, and spectroscopic comparison with gold(I) and copper(I) arylacetylides, Organometallics 21:2275 –2282.
- Sougoule AS, Balde CA, Keita N, Xiao X, Han X, Liang J, Zhu D (2015) A novel tetranuclear organotin(IV) carboxylate with chain structure: synthesis, crystal structure, and characterizations, Heteroat Chem 26:382 -390.
- See: Leonidova A, Gasser G, Underestimated potential of organometallic rhenium complexes as anticancer agents, ACS Chem. Biol. 2014, 9, 2180−2193 and the references cited therein.
- Collery P, Veena V, Harikrishnan A, Desmaele D (2019) The rhenium(I)- diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers. Invest New Drugs 37: 973 – 983. https://doi.org/10.1007/s10637-019-00727-1.
- He L, Pan Z-Y, Qin W-W, Li Y, Tan C-P, Mao Z-W (2019) Impairment of the autophagy-related lysosomal degradation pathway by an anticancer rhenium(I) complex. Dalton Trans 48:4398-4404.
- See: Liew HS, Mai C-W, Zulkefeli M, Madheswaran T, Kiew LV, Delsuc N, Low ML (2020) Recent Emergence of Rhenium(I) Tricarbonyl complexes as photosensitisers for cancer therapy. Molecules 25: 4176 and the references cited therein. doi:10.3390/molecules25184176
- See: Bauer EB, Haase AA, Reich RM, Crans DC, Kühn FE (2019) Organometallic and coordination rhenium compounds and their potential in cancer therapy. Coord Chem Rev 393:79 –117 and the references cited therein.
- Simpson PV, Casari I, Paternoster S, Skelton BW, Falasca M, Massi M (2017) Defining the anti‐cancer activity of tricarbonyl rhenium complexes: induction of G2/M cell cycle arrest and blockade of Aurora‐A kinase phosphorylation. Chem Eur J 23:6518 –6521.
- Domenichini A, Casari I, Simpson PV, Desai NM, Chen L, Dustin C, Edmands JS, Vliet A, Mohammadi M, Massi M, Falasca M (2020) Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signaling. J Exp Clin Cancer Res 39:276 https://doi.org/10.1186/s13046-020-01777-7.
[25] Collery P, Desmaele D, Vijaykumar V (2019) Design of rhenium compounds in
targeted anticancer therapeutics. Curr Pharm Des 25:3306 -3322.
[26] Delasoie J, Pavic A, Voutier N, Vojnovic S, Crochet A, Nikodinovic-Runic J, Zobi F
(2020) Identification of novel potent and non-toxic anticancer, anti-angiogenic and
antimetastatic rhenium complexes against colorectal carcinoma. Eur J Med
Chem 204:112583 https://doi.org/10.1016/j.ejmech.2020.112583
[27] Capper S, Packman H, Rehkämper M (2020) Rhenium-based complexes and in
vivo testing: a brief history miles. ChemBioChem 21:2111 –2115.
[28] Marker SC, King AP, Swanda RV, Vaughn B, Boros E, Q S-B, Wilson JJ (2020)
Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes.
Angew Chem Int Ed 59:13391 -13400.
[29] Pan Z-Y, Cai D-H, He L (2020) Dinuclear phosphorescent rhenium(I) complexes as
potential anticancer and photodynamic therapy agents. Dalton Trans 49:11583 –
11590.
[30] Wilder PT, Weber DJ, Winstead A, Parnell S, Hinton TV, Stevenson M, Giri D,
Azemati S, Olczak P, Powell BV, Odebode T, Tadesse S, Zhang Y, Pramanik SK,
Wachira JM, Ghimire S, McCarthy P, Barfield A, Banerjee HN, Chen C, Golen JA,
Rheingold AL, Krause JA, Ho DM, Zavalij PY, Shaw R, Mandal SK (2018)
Unprecedented anticancer activities of organorhenium sulfonato and carboxylato
complexes against hormone-dependent MCF-7 and hormone-independent triple-
negative MDA-MB-231 breast cancer cells. Mol Cell Biochem 441:151 -163.
[31] Stern O, Volmer M (1919) über die Abklingzeit der Fluoreszenz. Z Phys 20:183
-188.
[32] Cohen G, Eisenberg H (1969) Viscosity and sedimentation study of sonicated
DNA–proflavine complexes. Biopolymers 8:45 -55.
[33] Waring MJ (1965) Complex formation between ethidium bromide and nucleic
Acids. J Mol Biol 13:269 –282.
[34] Jiang M, Li Y-T, Wu Z-Y, Liu Z-Q, Yan C-W (2009) Synthesis, crystal structure,
cytotoxic activities and DNA-binding properties of new binuclear copper(II)
complexes bridged by N,N’-bis(N-hydroxyethylaminoethyl)oxamide. J Inorg
Biochem 103:833 –844.
[35] Anbu S, Kandaswamy M, Suthakaran P, Murugan V, Varghese B (2009) Structural,
magnetic, electrochemical, catalytic, DNA binding and cleavage studies of new
macrocyclic binuclear copper(II) complexes. J Inorg Biochem 103:401 -410.
[36] Biancalana L, Pratesi A, Chiellini F, Zacchini S, Funaioli T, Gabbiani C, Marchetti F
(2017) Ruthenium arene complexes with triphenylphosphane ligands: cytotoxic
activity towards pancreatic cancer cells, interaction with model proteins, and critical
effect of ethacrynic acid substitution. New J Chem 41:14574 -14588.
[37] Raveendran R, Braude JP, Wexselblatt E, Novohradsky V, Stuchlikova O, Brabec
V, Gandin V, Gibson D (2016) Pt(IV) derivatives of cisplatin and oxaliplatin with
phenylbutyrate axial ligands are potent cytotoxic agents that act by several
mechanisms of action. Chem Sci 7:2381 -2391.
[38] Banerjee HN, Boston A, Barfield A, Stevenson M, Sarkar FH, Giri D, Winstead A,
Krause JA, Mandal SK (2016) A study of the effects of novel rhenium compounds
on pancreatic and prostate cancer cell lines. Int J Sci Res 5: 481-483.
[39] Mbagu MK, Kebulu DN, Winstead A, Pramanik SK, Banerjee HN, Iwunze MO,
Wachira JM, Greco GE, Haynes GK, Sehmer A, Sarkar FH, Ho DM, Pike RD,
Mandal SK (2012) Fac-tricarbonyl(pentylcarbonato)(α-diimine)rhenium complexes:
one-pot synthesis, characterization, fluorescence studies, and cytotoxic activity
against human MDA-MB-231 breast, CCl-227 colon and BxPC-3 pancreatic
carcinoma cell lines. Inorg Chem Commun 21: 35-38.
[40] Han J, Liu L, Yue X, Chang J, Shi W, Hua Y (2013) A binuclear complex constituted
by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor
in pancreatic cancer cultures and xenografts. Toxicol Appl Pharmacol 273:477-483.
[41] Palepu NR, Adhikari S, Premkumar J R, Verma AK, Shepherd SL, Phillips RM,
Kaminsky W, Kollipara MR (2016) Half‐sandwich ruthenium, rhodium and iridium
complexes featuring oxime ligands: structural studies and preliminary investigation
of in vitro and in vivo anti‐tumour activities. Appl Organomet Chem 31: e3640.
https://doi.org/10.1002/aoc.3640
[42] Kowalski S, Wyrzykowski D, Hac S, Rychlowski M, Radomski MW, Inkielewicz-
Stepniak I. (2019) New oxidovanadium(IV) coordination complex containing 2-
methylnitrilotriacetate ligands induces cell cycle arrest and autophagy in human
pancreatic ductal adenocarcinoma cell lines. Int J Mol Sci 20: 261.
doi:10.3390/ijms20020261
[43] Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng,
Y-R, Page JE, Hemann MT, Lippard SJ (2015) Necroptosis-inducing rhenium(V)
oxo complexes. J Am Chem Soc 137:2967 −2974.
[44] Lee LC-C, Leung K-K, Lo KK-W (2017) Recent development of luminescent
rhenium(I) tricarbonyl polypyridine complexes as cellular imaging reagents,
anticancer drugs, and antibacterial agents. Dalton Trans 46:16357 -16380.
[45] Pigeon P, Top S, Vessières A, Huché M, Görmen M, El Arbi M, Plamont M-A,
McGlinchey MJ, Jaouen G (2011) A new series of ferrocifen derivatives, bearing
two aminoalkyl chains, with strong antiproliferative effects on breast cancer cells.
New J Chem 35:2212 -2218.
[46] Jaouen G, Vessières A, Top S (2015) Ferrocifen type anticancer drugs. Chem Soc
Rev 44:8802 -8817.
[47] Wang Y, Pigeon P, Top S, McGlinchey MJ, Jaouen G (2015) Organometallic
antitumor compounds: ferrocifens as precursors to quinone methides, Angew
Chem Int Ed 54:10230 -10233.
[48] Strese S, Fryknäs M, Larsson R, Gullbo J (2013) Effects of hypoxia on human
cancer cell line chemosensitivity. BMC Cancer 13: 331.
https://doi.org/10.1186/1471-2407-13-331
[49] Yan YK, Cho SE, Shaffer KA, Rowell JE, Barnes BJ, Hall IH (2000) Cytotoxicity of
rhenium(I) alkoxo and hydroxo carbonyl complexes in murine and human tumor
cells. Pharmazie 55: 307–313.
[50] Wang W, Yan YK, Hor TSA, Vittal JJ, Wheaton JR, Hall IH (2002) Synthesis,
X-ray structures, and cytotoxicity of rhenium(I) carbonyl 2-(dimethylamino)ethoxide
complexes. Polyhedron 21:1991 –1999.
[51] Zhang J, Vittal JJ, Henderson W, Wheaton JR, Hall IH, Hor TSA, Yan YK (2002)
Tricarbonylrhenium(I) complexes of phosphine-derivatized amines, amino acids
and a model peptide: structures, solution behavior and cytotoxicity J Organomet
Chem 650: 123–132.